Filing Flows › Regeneron Pharmaceuticals (REGN) › Next earnings date
Regeneron Pharmaceuticals (REGN) earnings: beat the estimate
Regeneron Pharmaceuticals (REGN) reported on Oct 30, 2026 and beat the EPS estimate: $20.07 against $16.25 (+23.5%). Revenue was $5.1B for Q3 2026, +36% year over year. It beat the EPS estimate in 100% of the quarters on record.
The last report
Regeneron Pharmaceuticals reported revenue of $5.1B for the third quarter 2026 (+36% Y/Y), net earnings $1.9B: Collaboration revenue $3.0B, Net product sales $1.8B, Other revenue $310M, Lynozyfic $19.0M. How it makes money → · Every quarter →
Regeneron Pharmaceuticals' latest quarter
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
Did Regeneron Pharmaceuticals beat earnings?
Regeneron Pharmaceuticals (REGN) reported on Oct 30, 2026 and beat the EPS estimate: $20.07 against $16.25 (+23.5%).
When does REGN report earnings?
The next date is not set yet.
Does Regeneron Pharmaceuticals usually beat earnings?
It beat the consensus EPS estimate in 100% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.